The transaction eliminates about US$842 million of Parallel debt and gives SNDL a path to direct, consolidated exposure to U.S. medical cannabis operations, subject to legal, regulatory, accounting and Nasdaq requirements.
verifying reliability
No specialized terms available for this topic.